Topical JAK3 Formulation for Cutaneous Lupus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cutaneous lupus erythematosus, particularly discoid lupus erythematosus, are unsatisfactory as they often lead to side effects such as skin atrophy and retinal toxicity, and there is a need for effective topical therapies that do not cause systemic adverse effects.
Innovation Solution
A pharmaceutical formulation comprising a therapeutically effective amount of Compound I, a JAK3 and Syk kinase inhibitor, combined with a topical base, antioxidant, and penetration enhancers, is developed for topical administration to treat cutaneous lupus, aiming to reduce lesion severity without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (corticosteroids or immunosuppressants) are administered for cutaneous lupus, then the disease symptoms are suppressed, but skin atrophy and systemic side effects occur
Solution Approach 1:
The patent uses a topical formulation as an intermediary delivery system that contains the JAK3 inhibitor compound. This formulation enables localized drug delivery to the skin, allowing the active ingredient to act directly at the disease site while minimizing systemic absorption and associated side effects
Solution Approach 2:
The invention applies local treatment by formulating the JAK3 inhibitor for topical administration directly to affected skin areas. This localized approach concentrates the therapeutic effect where needed while reducing exposure of healthy tissues and systemic circulation to the drug, thereby minimizing side effects like skin atrophy
2Object-affected harmful factors
If topical formulations are developed to reduce systemic side effects, then safety is improved, but drug penetration and effectiveness may be compromised
Solution Approach 1:
The patent modifies the physical and chemical parameters of the drug delivery system by creating a topical formulation with specific vehicle components, concentrations, and physicochemical properties. These parameter changes optimize both skin penetration capability and localized drug retention, ensuring therapeutic effectiveness while maintaining safety
Data Source
AI summary
Embodiments of topical formulations for administering compound I or a pharmaceutically acceptable salt or solvate thereof are disclosed. Embodiments of methods for using the topical formulations in the treatment of dermatological disorders such as cutaneous collagen vascular diseases, e.g., cutaneous lupus, also are disclosed.